Our results suggest that these effects are on different causal pathways, raising the possibility that targeted treatments could be developed to inhibit HMGCR in a more specific way that lowers CAD risk without increasing T2D risk. The gene discussed is HMGCR; the disease is type 2 diabetes mellitus.